Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Operating Expenses (2022 - 2025)

Zentalis Pharmaceuticals has reported Operating Expenses over the past 4 years, most recently at $37.4 million for Q4 2025.

  • Quarterly results put Operating Expenses at $37.4 million for Q4 2025, down 51.26% from a year ago — trailing twelve months through Dec 2025 was $152.8 million (down 40.91% YoY), and the annual figure for FY2025 was $152.8 million, down 40.91%.
  • Operating Expenses for Q4 2025 was $37.4 million at Zentalis Pharmaceuticals, up from $33.7 million in the prior quarter.
  • Over the last five years, Operating Expenses for ZNTL hit a ceiling of $103.9 million in Q2 2023 and a floor of $33.7 million in Q3 2025.
  • Median Operating Expenses over the past 4 years was $60.3 million (2022), compared with a mean of $58.6 million.
  • Biggest five-year swings in Operating Expenses: soared 63.75% in 2023 and later crashed 51.26% in 2025.
  • Zentalis Pharmaceuticals' Operating Expenses stood at $51.8 million in 2022, then surged by 31.24% to $67.9 million in 2023, then increased by 12.94% to $76.7 million in 2024, then crashed by 51.26% to $37.4 million in 2025.
  • The last three reported values for Operating Expenses were $37.4 million (Q4 2025), $33.7 million (Q3 2025), and $36.1 million (Q2 2025) per Business Quant data.